Germany-based Boehringer Ingelheim has received a contract from the United States Department of Agriculture for supplying a vaccine bank that will protect US livestock from foot-and-mouth disease, it was reported on Wednesday.
The contract requires the company to develop and maintain a strategic reserve of frozen vaccine antigen concentrate that the company can formulate into a vaccine for the disease in case of an outbreak in the US.
Steve Boren, vice president of the US Livestock Business at Boehringer Ingelheim Animal Health, said, 'As a global leader in the storage and management of FMD vaccine banks, with FMD expertise dating back more than 70 years, Boehringer Ingelheim constantly monitors emerging disease threats.'
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses